Global Markets for Drug Device Combinations
November 27, 2012
Wellesley, Mass. – According to a new technical market research report, GLOBAL MARKETS FOR DRUG DEVICE COMBINATIONS (PHM045C) from BCC Research (www.bccresearch.com), the market for global drug device combination products was valued at $18.5 billion in 2011 and should reach $19 billion in 2012. Total market value is expected to reach $30.5 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 9.9%.
The market for drug device combination products can be broken down into five major segments: coronary stents, photodynamic therapies, antimicrobial catheters, orthopedic applications, and all other segments.
Coronary stents are expected to have a value of $5.8 billion in 2012 and $8.2 billion in 2017, a CAGR of 7.2%.
Photodynamic therapies as a segment should total $1.7 billion in 2012 and $2.6 billion in 2017, a CAGR of 8.9%.
Antimicrobial catheters are expected to total $6.6 billion in 2012 and $11.7 billion in 2017, a CAGR of 12.1%.
The segment made up of orthopedic applications (cements and bone substitutes) should be valued at $2.8 billion in 2012 and $4.1 billion in 2017, a CAGR of 7.9%.
The combination products industry includes makers of drug-delivery systems, gene therapy systems, personalized medicine drug device combinations, biological-device combinations, nanotechnology, and certain other products for diagnostic and therapeutic treatments of cardiovascular, metabolic, oncologic, and other disorders.
Combination products are therapeutic and/or diagnostic products that combine elements of drugs, devices, and/or biological products. An estimated 30% of all new healthcare products under development are “combination products” involving medical devices embedded with pharmaceutical or biologics components. The classic example of a combination product that revolutionized patient care is the drug-eluting coronary stent.
This report will help its readers:
- Forecast the market size for drug device combination products in terms of dollar and unit sales
- Classify the market size for drug device combination products by geographical region in terms of dollar and unit sales
- Highlight the roles played by major stakeholders and players
- Provide an overview of the activities of influential companies
- Examine crucial, innovative breakthroughs by means of a detailed patent analysis.
This report will be valuable to many industry participants, including the following:
- Drug delivery system makers
- Drug device manufacturers
- End users and distributors
- Academic and research institutions
- Financial institutions.
Global Markets for Drug-Device Combinations( PHM045C )
Publish Date: Jan 2013
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.
BCC Library Membership Benefits
Unlimited Access to Market Research Reports for Academic Institutions and Corporations.
Custom Research
Tailored solutions across industries for your unique business needs.
More in Pharmaceuticals
- Global Bispecific Antibodies Market to Reach $22.3 Billion by 2030 as Immuno-Oncology Innovation and R&D Investment Accelerate
- Neuroprotective Agents Market to Reach $60.9 Billion by 2030 as Neurological Disease Burden and Aging Populations Drive Pharmaceutical Investment
- Radioligand Therapeutics Market to More Than Double to $4.8 Billion by 2030 as Targeted Cancer Treatments Gain Regulatory Momentum
- Global GLP-1 Analogues Market to Reach $268.4 Billion by 2030
- AI in Clinical Trials Poised for Rapid Growth with a 22.6% CAGR Forecast
Reports from Pharmaceuticals
Recent News
- Biometrics as a Service in Medical Devices to Reach $2.7 Billion by 2030, Driven by Remote Patient Monitoring Demand
- Protein Synthesis Research Market to Reach $42.8 Billion by 2031, Driven by Surging CGT Investment
- AI and Advanced Diagnostics Transform Cancer Detection Market Amid Rising Healthcare Investment
- Global Noninvasive Cancer Diagnostics Market to Reach $165.2 Billion by 2030 as Liquid Biopsy, AI-Enabled Screening and Multi-Cancer Detection Tests Transform Oncology
- Cloud Computing in Cell Biology, Genomics and Drug Development to Reach $15.6 Billion by 2030 as Biological Data Explosion Drives Demand